Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:15:36 2024-09-10 EDT 5-day change 1st Jan Change
340.84 USD +0.43% Intraday chart for Medpace Holdings, Inc. -2.51% +11.28%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Medpace Holdings Insider Sold Shares Worth $3,175,463, According to a Recent SEC Filing MT
Skanska Builds New Office Building in Cincinnati, Ohio, USA, for USD 164 Million, About SEK 1.7 Billion CI
New entries in MarketScreener's USA portfolio Our Logo
Truist Starts Medpace Holdings With Hold Rating, $415 Price Target MT
UBS Adjusts Medpace Holdings Price Target to $420 From $480, Maintains Buy Rating MT
TD Cowen Adjusts Price Target on Medpace to $434 From $452, Maintains Buy Rating MT
Musk magic fizzles, Alphabet stumbles, and stock markets feel the blues Our Logo
Deutsche Bank Adjusts Medpace Holdings Price Target to $336 From $395, Maintains Hold Rating MT
Analyst recommendations: Colgate, Lockheed Martin, Procter & Gamble, Eli Lilly, Tesla... Our Logo
Sector Update: Health Care Stocks Edge Higher Late Afternoon MT
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
Sector Update: Health Care MT
Medpace Shares Fall After Q2 EPS, Revenue Increase, Updates Guidance MT
Transcript : Medpace Holdings, Inc., Q2 2024 Earnings Call, Jul 23, 2024
Traders Eye Tech Earnings as US Equity Futures Post Narrow Losses Pre-Bell MT
Top Premarket Decliners MT
Medpace Q2 EPS, Revenue Increase, Updates Guidance; Shares Fall After-Hours MT
Medpace Guides For Full Year 2024 GAAP EPS of $11.24-$11.93 on Revenue of $2.125-$2.175 Billion, vs CIQ Analyst Consensus of $11.24/Share on Revenue of $2.17 Billion MT
Earnings Flash (MEDP) MEDPACE HOLDINGS Reports Q2 Revenue $528.1M, vs. Street Est of $528.4M MT
Tranche Update on Medpace Holdings, Inc.'s Equity Buyback Plan announced on October 24, 2022. CI
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 CI
Medpace Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
Make way for earnings season Our Logo
Analyst recommendations: Albemarle, Snowflake, Tesla, Diageo, Johnson Matthey... Our Logo
Baird Adjusts Medpace Holdings' Price Target to $469 From $456, Keeps Outperform Rating MT
Chart Medpace Holdings, Inc.
More charts
Logo Medpace Holdings, Inc.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
Employees
5,800
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
339.38USD
Average target price
406.91USD
Spread / Average Target
+19.90%
Consensus
  1. Stock Market
  2. Equities
  3. MEDP Stock
  4. News Medpace Holdings, Inc.
  5. UBS Adjusts Medpace Holdings Price Target to $420 From $480, Maintains Buy Rating
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW